Boehringer eyes immuno-oncology; Roche plans more 'small' deals in 2015;

@FierceBiotech: Intrexon and Ziopharm buy into CAR-T in $100M deal. Story | Follow @FierceBiotech

@JohnCFierce: First #FDA approved obesity device since 2007. More | Follow @JohnCFierce

> Boehringer Ingelheim is buying into the promise of immunotherapies for cancer, signing a deal with Yale University to develop treatments that use the body's natural defenses to fight tumors. More

> Roche ($RHHBY) plans to consider its spree of bolt-on acquisitions in the new year, CFO Alan Hippe told Bloomberg, eschewing blockbuster mergers in favor of targeted M&A. "This continuous flow of rather small acquisitions makes total sense," Hippe said. Story

> Gene therapy specialist uniQure ($QURE) signed a deal with startup Treeway to develop a treatment for amyotrophic lateral sclerosis (ALS). News

Medical Device News

@FierceMedDev: This week's edition of FierceDiagnostics, hot off the press. | Follow @FierceMedDev

@StacyALawrence: ICYMI: JP Morgan: With $1.5B spent and a new president, NantHealth works to rationalize patient care. Report | Follow @StacyALawrence

@EmilyWFierce: Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. FiercePharmaMarketing story | Follow @EmilyWFierce

> Bard loses bid to delay vaginal mesh trial proceedings. Article

> DexCom: new CEO reports patient base grew by 50% in 2014. More

> Stakeholders look for clues to FDA's 2015 intentions regarding health IT. Story

Pharma News

@FiercePharma:  JPM: $GSK ready to shift off Advair; $TEVA CEO lists buyout reqs; $PFE building PCSK9 "franchise." Article | Follow @FiercePharma

@CarlyHFierce:  Big Pharma vs. 'growth pharma'? Let Actavis chief detail the differences. More | Follow @CarlyHFierce

> With hep C price deals made, Express Scripts eyes PCSK9 meds--and then cancer. Article

> German cost gatekeeper spurns Gilead's Zydelig for CLL. Story

> Drug adherence gets a boost from gamification, new study says. More

Drug Delivery News

> Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents. More

> Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story

> Pill-maker Capsugel collects Australian uni's tech for greater bioavailability. Article

> Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality. Item

> Alnylam and Isis strengthen RNAi alliance, agree to swap IP. More

Diagnostics News

> Roche snatches up majority share in Foundation Medicine for $1B plus milestones. News

> Biocept joins up with Insight Genetics for lung cancer test. Report

> Qiagen acquires Enzymatics, gains NGS partner ArcherDX. Story

> Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx. More

> Qiagen exceeds 2014 placement goals for molecular Dx, hedges its bets on continued success. Article

Pharma Marketing News

> Shire CEO sees 'home turf' marketing advantage with NPS buy. Report

> Actavis CEO: We may be big, but we don't want to be Big Pharma. News

> Some ad types are calling it: 'Pharmageddon' is over. DTC is back. Article

> Turning drug adherence into a game actually works, study finds. Report

> Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.